Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Tvardi Therapeutics, Inc.CARA · Entity 7579 | Director · President & CEO | September 07, 2021 | September 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Tvardi Therapeutics, Inc.
Report date September 07, 2021 · Filed September 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 991,405 |
Reported balance
After 2021-09-07 transaction · row 1
1 source rowRow 1 · 2021-09-07 · Sale · Disposed 20,000 · Balance 991,405 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.34 to $15.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.34 to $15.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 09, 2018 Filed Mar 13, 2018 18:35 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 187,500 | $0.00 Strike: $14.39 | $0.00 |
DisclosureSEC source: 0001209191-18-019398 · doc4.xml · derivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,500 Underlying: Common Stock · 187,500 shares Expires 2028-03-09 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 9, 2018, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 17:13 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 5,400 | $15.00 | $81,000.00 |
DisclosureSEC source: 0001209191-18-012008 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,071,392 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.05, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| January 25, 2018 Filed Jan 26, 2018 17:52 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001209191-18-005678 · doc4.xml · derivative · entry 3 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 191,000 Underlying: Common Stock · 3,000 shares Expires 2026-03-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
| January 25, 2018 Filed Jan 26, 2018 17:52 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 3,000 | $6.00 | $18,000.00 |
DisclosureSEC source: 0001209191-18-005678 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,076,792 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 24, 2018 Filed Jan 26, 2018 17:52 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 12,500 | $15.00 | $187,500.00 |
DisclosureSEC source: 0001209191-18-005678 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,073,792 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017. Read SEC document |
| November 03, 2017 Filed Nov 3, 2017 17:27 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-17-059277 · doc4.xml · derivative · entry 3 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2017-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| November 03, 2017 Filed Nov 3, 2017 17:27 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 20,000 | $2.48 | $49,600.00 |
DisclosureSEC source: 0001209191-17-059277 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,086,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 01, 2017 Filed Nov 3, 2017 17:27 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 16,000 | $12.66 | $202,560.00 |
DisclosureSEC source: 0001209191-17-059277 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,066,292 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.55 - $12.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 18:10 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $2.48 | $0.00 |
DisclosureSEC source: 0001209191-17-045567 · doc4.xml · derivative · entry 3 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 10,000 shares Expires 2017-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Immediately exercisable. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 18:10 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | SaleCommon Stock | 25,000 | $15.05 | $376,250.00 |
DisclosureSEC source: 0001209191-17-045567 · doc4.xml · nonDerivative · entry 2 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,082,292 F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 15, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 - $15.135, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 18:10 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | Exercise / conversionCommon Stock | 10,000 | $2.48 | $24,800.00 |
DisclosureSEC source: 0001209191-17-045567 · doc4.xml · nonDerivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,107,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2017 Filed Mar 10, 2017 17:22 UTC | Tvardi Therapeutics, Inc. CARA · Entity 7579 | GrantEmployee Stock Option (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $17.41 | $0.00 |
DisclosureSEC source: 0001209191-17-019917 · doc4.xml · derivative · entry 1 CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2027-03-08 F1 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 8, 2017, in each case subject to the Reporting Person's Continuous service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.